The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
White matter hyperintensities are a core feature of Alzheimer’s disease: evidence from the dominantly inherited Alzheimer network
Open accessAbstract
OBJECTIVE: White matter hyperintensities (WMHs) are areas of increased signal on T2-weighted magnetic resonance imaging (MRI) scans that most commonly reflect small vessel cerebrovascular disease. Increased WMH volume is associated with risk and progression of Alzheimer's disease (AD). These observations are typically interpreted as evidence that vascular abnormalities play an additive, independent role contributing to symptom presentation, but not core features of AD. We examined the severity and distribution of WMH in presymptomatic PSEN1, PSEN2, and APP mutation carriers to determine the extent to which WMH manifest in individuals genetically determined to develop AD. METHODS: The study comprised participants (n = 299; age = 39.03 ± 10.13) from the Dominantly Inherited Alzheimer Network, including 184 (61.5%) with a mutation that results in AD and 115 (38.5%) first-degree relatives who were noncarrier controls. We calculated the estimated years from expected symptom onset (EYO) by subtracting the affected parent's symptom onset age from the participant's age. Baseline MRI data were analyzed for total and regional WMH. Mixed-effects piece-wise linear regression was used to examine WMH differences between carriers and noncarriers with respect to EYO. RESULTS: Mutation carriers had greater total WMH volumes, which appeared to increase approximately 6 years before expected symptom onset. Effects were most prominent for the parietal and occipital lobe, which showed divergent effects as early as 22 years before estimated onset. INTERPRETATION: Autosomal-dominant AD is associated with increased WMH well before expected symptom onset. The findings suggest the possibility that WMHs are a core feature of AD, a potential therapeutic target, and a factor that should be integrated into pathogenic models of the disease. Ann Neurol 2016;79:929-939.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“findings from previous studies have also shown that WMHs often occur prior to the presence of amyloid-β plaques in preclinical AD [19,20,21]”
From Amyloid-PET and White Matter Hyperintensities Have Independent Effects on Baseline Cognitive Function and Synergistic Effects on Longitudinal Executive Function (2023) · cites this paper as [19]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Emerging evidence suggests that white matter microstructural changes may be not only a marker of small vessel injury but also directly related to AD pathology. 53 , 54”
From White matter hyperintensity modulates the amyloid‐tau‐cognition association and anti‐amyloid treatment efficacy in asymptomatic older adults (2025) · cites this paper as [53]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“WMHs are considered an MRI detectable marker of white matter changes due to microvascular pathology, and are increased in autosomal-dominant Alzheimer’s disease (Lee et al., 2016).”
From White matter diffusion alterations precede symptom onset in autosomal dominant Alzheimer’s disease (2018) · cites this paper as Lee et al., 2016
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Robust Locally Weighted Regression and Smoothing Scatterplots
Cleveland, W. S. (1979) · Journal of the American Statistical Association · doi:10.1080/01621459.1979.10481038 · Cited by 11,594
Jack, C. R., Knopman, D. S., Jagust, W. J., Petersen, R. C., Weiner, M. W., Aisen, P. S., Shaw, L. M., Vemuri, P., Wiste, H. J., Weigand, S. D., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70291-0 · Cited by 4,396
Clinical and biomarker changes in dominantly inherited Alzheimer's disease
Bateman, R. J., Xiong, C., Benzinger, T. L. S., Fagan, A. M., Goate, A., Fox, N. C., Marcus, D. S., Cairns, N. J., Xie, X., Blazey, T. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202753 · Cited by 3,814
Self-citationGorelick, P. B., Scuteri, A., Black, S. E., DeCarli, C., Greenberg, S. M., Iadecola, C., Launer, L. J., Laurent, S., Lopez, O. L., Nyenhuis, D., et al. (2011) · Stroke · doi:10.1161/str.0b013e3182299496 · Cited by 3,811
Pantoni, L. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70104-6 · Cited by 3,405
Neurovascular pathways to neurodegeneration in Alzheimer’s disease and other disorders
Zlokovic, B. V. (2011) · Nature Reviews Neuroscience · doi:10.1038/nrn3114 · Cited by 2,969
Regional Brain Changes in Aging Healthy Adults: General Trends, Individual Differences and Modifiers
Raz, N., Lindenberger, U., Rodrigue, K. M., Kennedy, K. M., Head, D., Williamson, A., Dahle, C., Gerstorf, D., & Acker, J. D. (2005) · Cerebral Cortex · doi:10.1093/cercor/bhi044 · Cited by 2,875
Debette, S., & Markus, H. S. (2010) · BMJ · doi:10.1136/bmj.c3666 · Cited by 2,328
Mixed brain pathologies account for most dementia cases in community-dwelling older persons
Schneider, J. A., Arvanitakis, Z., Bang, W., & Bennett, D. A. (2007) · Neurology · doi:10.1212/01.wnl.0000271090.28148.24 · Cited by 1,992
Primary age-related tauopathy (PART): a common pathology associated with human aging
Crary, J. F., Trojanowski, J. Q., Schneider, J. A., Abisambra, J. F., Abner, E. L., Alafuzoff, I., Arnold, S. E., Attems, J., Beach, T. G., Bigio, E. H., et al. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1349-0 · Cited by 1,467
Self-citation
Flagged first, then by citations
Research works printed but not linked: 1
- 10.1080/01621459.1970.10481147 · DOI
Cited by
Sorted by citations
White matter changes in Alzheimer’s disease: A focus on myelin and oligodendrocytes
Nasrabady, S. E., Rizvi, B., Goldman, J. E., & Brickman, A. M. (2018) · Acta Neuropathologica Communications · doi:10.1186/s40478-018-0515-3 · Cited by 723
Self-citationVascular dysfunction—The disregarded partner of Alzheimer's disease
Sweeney, M. D., Montagne, A., Sagare, A. P., Nation, D. A., Schneider, L. S., Chui, H. C., Harrington, M. G., Pa, J., Law, M., Wang, D. J. J., et al. (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.07.222 · Cited by 711
Babulal, G. M., Quiroz, Y. T., Albensi, B. C., Arenaza‐Urquijo, E., Astell, A. J., Babiloni, C., Bahar‐Fuchs, A., Bell, J., Bowman, G. L., Brickman, A. M., et al. (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.09.009 · Cited by 528
White matter aging drives microglial diversity
Safaiyan, S., Besson-Girard, S., Kaya, T., Cantuti-Castelvetri, L., Liu, L., Ji, H., Schifferer, M., Gouna, G., Usifo, F., Kannaiyan, N., et al. (2021) · Neuron · doi:10.1016/j.neuron.2021.01.027 · Cited by 477
Alber, J., Alladi, S., Bae, H., Barton, D. A., Beckett, L. A., Bell, J. M., Berman, S. E., Biessels, G. J., Black, S. E., Bos, I., et al. (2019) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1016/j.trci.2019.02.001 · Cited by 455
White matter and cognition: making the connection
Filley, C. M., & Fields, R. D. (2016) · Journal of Neurophysiology · doi:10.1152/jn.00221.2016 · Cited by 479
Yin, F. (2023) · The FEBS Journal · doi:10.1111/febs.16344 · Cited by 441
Sadick, J. S., O’Dea, M. R., Hasel, P., Dykstra, T., Faustin, A., & Liddelow, S. A. (2022) · Neuron · doi:10.1016/j.neuron.2022.03.008 · Cited by 415
Sen, A., Jetté, N., Husain, M., & Sander, J. W. A. S. (2020) · The Lancet · doi:10.1016/s0140-6736(19)33064-8 · Cited by 379
Alzheimer's disease associated with Down syndrome: a genetic form of dementia
Fortea, J., Zaman, S. H., Hartley, S., Rafii, M. S., Head, E., & Carmona-Iragui, M. (2021) · The Lancet Neurology · doi:10.1016/s1474-4422(21)00245-3 · Cited by 357
Zhan, X., Stamova, B. S., & Sharp, F. R. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00042 · Cited by 361
Beyond the neuron–cellular interactions early in Alzheimer disease pathogenesis
Henstridge, C. M., Hyman, B. T., & Spires-Jones, T. L. (2019) · Nature Reviews Neuroscience · doi:10.1038/s41583-018-0113-1 · Cited by 348
Montagne, A., Nikolakopoulou, A. M., Zhao, Z., Sagare, A. P., Si, G., Lazic, D., Barnes, S. R., Daianu, M., Ramanathan, A., Go, A., et al. (2018) · Nature Medicine · doi:10.1038/nm.4482 · Cited by 344
RetractedVascular Cognitive Impairment (VCI)
Rundek, T., Tolea, M. I., Ariko, T., Fagerli, E. A., & Camargo, C. J. (2021) · Neurotherapeutics · doi:10.1007/s13311-021-01170-y · Cited by 347
The human connectome in Alzheimer disease — relationship to biomarkers and genetics
Yu, M., Sporns, O., & Saykin, A. J. (2021) · Nature Reviews Neurology · doi:10.1038/s41582-021-00529-1 · Cited by 265
Self-citationElahi, F. M., Casaletto, K. B., Joie, R. L., Walters, S. M., Harvey, D. J., Wolf, A. A., Edwards, L., Contreras, W. R., Karydas, A., Cobigo, Y., et al. (2019) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2019.09.004 · Cited by 258
Homeostasis and metabolism of iron and other metal ions in neurodegenerative diseases
Chen, L., Shen, Q., Liu, Y., Zhang, Y., Sun, L., Ma, X., Song, N., & Xie, J. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02071-0 · Cited by 279
The increasing impact of cerebral amyloid angiopathy: essential new insights for clinical practice
Banerjee, G., Carare, R. O., Cordonnier, C., Greenberg, S. M., Schneider, J. A., Smith, E. E., van Buchem, M. A., van der Grond, J., Verbeek, M. M., & Werring, D. J. (2017) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2016-314697 · Cited by 251
Advances in Understanding the Pathophysiology of Lacunar Stroke
Regenhardt, R. W., Das, A. S., Lo, E. H., & Caplan, L. R. (2018) · JAMA Neurology · doi:10.1001/jamaneurol.2018.1073 · Cited by 237
Common genetic variation influencing human white matter microstructure
Zhao, B., Li, T., Yang, Y., Wang, X., Luo, T., Shan, Y., Zhu, Z., Xiong, D., Hauberg, M. E., Bendl, J. M., et al. (2021) · Science · doi:10.1126/science.abf3736 · Cited by 222
Cognitive impact of COVID-19: looking beyond the short term
Miners, J. S., Kehoe, P. G., & Love, S. (2020) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-00744-w · Cited by 261
Emerging Concepts in Vascular Dementia: A Review
Bir, S. C., Khan, M. W., Javalkar, V., Toledo, E. G., & Kelley, R. E. (2021) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2021.105864 · Cited by 247
Genome-wide association study of MRI markers of cerebral small vessel disease in 42,310 participants
Persyn, E., Hanscombe, K. B., Howson, J. M. M., Lewis, C. M., Traylor, M., & Markus, H. S. (2020) · Nature Communications · doi:10.1038/s41467-020-15932-3 · Cited by 208
Nemes-Baran, A. D., White, D. R., & DeSilva, T. M. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108047 · Cited by 196
White matter diffusion alterations precede symptom onset in autosomal dominant Alzheimer’s disease
Araque Caballero, M. Á., Suárez-Calvet, M., Duering, M., Franzmeier, N., Benzinger, T., Fagan, A. M., Bateman, R. J., Jack, C. R., Levin, J., Dichgans, M., et al. (2018) · Brain · doi:10.1093/brain/awy229 · Cited by 184
“WMHs are considered an MRI detectable marker of white matter changes due to microvascular pathology, and are increased in autosomal-dominant Alzheimer’s disease (Lee et al., 2016).”
BackgroundHabes, M., Pomponio, R., Shou, H., Doshi, J., Mamourian, E., Erus, G., Nasrallah, I., Launer, L. J., Rashid, T., Bilgel, M., et al. (2021) · Alzheimer's & Dementia · doi:10.1002/alz.12178 · Cited by 173
Self-citationWhite matter hyperintensity topography in Alzheimer's disease and links to cognition
Garnier‐Crussard, A., Bougacha, S., Wirth, M., Dautricourt, S., Sherif, S., Landeau, B., Gonneaud, J., De Flores, R., de la Sayette, V., Vivien, D., et al. (2022) · Alzheimer's & Dementia · doi:10.1002/alz.12410 · Cited by 170
Apoε4 disrupts neurovascular regulation and undermines white matter integrity and cognitive function
Koizumi, K., Hattori, Y., Ahn, S. J., Buendia, I., Ciacciarelli, A., Uekawa, K., Wang, G., Hiller, A., Zhao, L., Voss, H. U., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06301-2 · Cited by 179
A global view of the genetic basis of Alzheimer disease
Reitz, C., Pericak‐Vance, M. A., Foroud, T., & Mayeux, R. P. (2023) · Nature Reviews Neurology · doi:10.1038/s41582-023-00789-z · Cited by 181
Atrophy subtypes in prodromal Alzheimer’s disease are associated with cognitive decline
ten Kate, M., Dicks, E., Visser, P. J., van der Flier, W. M., Teunissen, C. E., Barkhof, F., Scheltens, P., Tijms, B. M., & Initiative, A. D. N. (2018) · Brain · doi:10.1093/brain/awy264 · Cited by 150
Dahl, M. J., Mather, M., Werkle‐Bergner, M., Kennedy, B. L., Guzman, S. J., Hurth, K. M., Miller, C. A., Qiao, Y., Shi, Y., Chui, H. C., et al. (2021) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2021.11.006 · Cited by 149
Habes, M., Sotiras, A., Erus, G., Toledo, J. B., Janowitz, D., Wolk, D. A., Shou, H., Bryan, R. N., Doshi, J. J., Völzke, H., et al. (2018) · Neurology · doi:10.1212/wnl.0000000000006116 · Cited by 147
Objective subtle cognitive difficulties predict future amyloid accumulation and neurodegeneration
Thomas, K. R., Bangen, K. J., Weigand, A. J., Edmonds, E. C., Wong, C. G., Cooper, S., Delano‐Wood, L., Bondi, M. W., & Initiative, A. D. N. (2019) · Neurology · doi:10.1212/wnl.0000000000008838 · Cited by 144
White matter hyperintensities in Alzheimer's disease: Beyond vascular contribution
Garnier‐Crussard, A., Cotton, F., Krolak‐Salmon, P., & Chételat, G. (2023) · Alzheimer's & Dementia · doi:10.1002/alz.13057 · Cited by 139
Dementia risk and prevention by targeting modifiable vascular risk factors
Tariq, S., & Barber, P. A. (2017) · Journal of Neurochemistry · doi:10.1111/jnc.14132 · Cited by 140
Associations between amyloid β and white matter hyperintensities: A systematic review
Roseborough, A. D., Ramirez, J., Black, S. E., & Edwards, J. D. (2017) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2017.01.026 · Cited by 139
van den Berg, E., Geerlings, M. I., Biessels, G. J., Nederkoorn, P. J., & Kloppenborg, R. P. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-170573 · Cited by 138
Martins, R. N., Villemagne, V., Sohrabi, H. R., Chatterjee, P., Shah, T. M., Verdile, G., Fraser, P., Taddei, K., Gupta, V. B., Rainey-Smith, S. R., et al. (2018) · Journal of Alzheimer’s Disease · doi:10.3233/jad-171145 · Cited by 129
Self-citationCauses and consequences of baseline cerebral blood flow reductions in Alzheimer’s disease
Bracko, O., Hernández, J. C. C., Park, L., Nishimura, N., & Schaffer, C. B. (2021) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x20982383 · Cited by 127
Evaluation of Ocular Perfusion in Alzheimer’s Disease Using Optical Coherence Tomography Angiography
Lahme, L., Esser, E. L., Mihailovic, N., Schubert, F., Lauermann, J. L., Johnen, A., Eter, N., Duning, T., & Alnawaiseh, M. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180738 · Cited by 126
The effect of white matter hyperintensities on cognition is mediated by cortical atrophy
Rizvi, B. M., Narkhede, A., Last, B. S., Budge, M., Tosto, G., Manly, J. J., Schupf, N., Mayeux, R. P., & Brickman, A. M. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2017.12.006 · Cited by 131
Llorens, F., Hermann, P., Villar‐Piqué, A., Lucena, D. D., Nägga, K., Hansson, O., Santana, I. J., Schmitz, M., Schmidt, C., Varges, D., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-14373-2 · Cited by 115
Bangen, K. J., Werhane, M. L., Weigand, A. J., Edmonds, E. C., Delano‐Wood, L., Thomas, K. R., Nation, D. A., Evangelista, N. D., Clark, A. L., Liu, T. T., et al. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00270 · Cited by 118
COVID-19 and Alzheimer’s Disease
Ciaccio, M., Sasso, B. L., Scazzone, C., Gambino, C. M., Ciaccio, A. M., Bivona, G., Piccoli, T., Giglio, R. V., & Agnello, L. (2021) · Brain Sciences · doi:10.3390/brainsci11030305 · Cited by 116
Dadar, M., Pascoal, T. A., Manitsirikul, S., Misquitta, K., Fonov, V., Tartaglia, M. C., Breitner, J. C. S., Rosa‐Neto, P., Carmichael, O. T., DeCarli, C. S., et al. (2017) · IEEE Transactions on Medical Imaging · doi:10.1109/tmi.2017.2693978 · Cited by 107
Alosco, M. L., Stein, T. D., Tripodis, Y., Chua, A. S., Kowall, N. W., Huber, B. R., Goldstein, L. E., Cantu, R. C., Katz, D. I., Palmisano, J. N., et al. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2019.2244 · Cited by 110
Interplay between Brain Pericytes and Endothelial Cells in Dementia
Procter, T. V., Williams, A., & Montagne, A. (2021) · The American Journal of Pathology · doi:10.1016/j.ajpath.2021.07.003 · Cited by 106
White matter hyperintensities are common in midlife and already associated with cognitive decline
d’Arbeloff, T. C., Elliott, M. L., Knodt, A. R., Melzer, T. R., Keenan, R. J., Ireland, D. R., Ramrakha, S., Poulton, R., Anderson, T., Caspi, A., et al. (2019) · Brain Communications · doi:10.1093/braincomms/fcz041 · Cited by 108
Jiang, J., Liu, T., Zhu, W., Koncz, R., Liu, H., Lee, T., Sachdev, P. S., & Wen, W. X. (2018) · NeuroImage · doi:10.1016/j.neuroimage.2018.03.050 · Cited by 100
Lee, S., Zimmerman, M. E., Narkhede, A., Nasrabady, S. E., Tosto, G., Meier, I. B., Benzinger, T. L. S., Marcus, D. S., Fagan, A. M., Fox, N. C., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0195838 · Cited by 100
Phuah, C., Chen, Y., Strain, J. F., Yechoor, N., Laurido-Soto, O., Ances, B. M., Lee, J., & Initiative, A. D. N. (2022) · Neurology · doi:10.1212/wnl.0000000000201186 · Cited by 102
Staffaroni, A., Elahi, F., McDermott, D., Marton, K., Karageorgiou, E., Sacco, S., Paoletti, M., Caverzasi, E., Hess, C., Rosen, H., et al. (2017) · Seminars in Neurology · doi:10.1055/s-0037-1608808 · Cited by 91
Blood will out: vascular contributions to Alzheimer’s disease
Strickland, S. (2018) · Journal of Clinical Investigation · doi:10.1172/jci97509 · Cited by 97
Cerebrovascular disease promotes tau pathology in Alzheimer’s disease
Laing, K. K., Simoes, S., Baena-Caldas, G. P., Lao, P. J., Kothiya, M., Igwe, K. C., Chesebro, A. G., Houck, A. L., Pedraza, L., Hernandez, A. I., et al. (2020) · Brain Communications · doi:10.1093/braincomms/fcaa132 · Cited by 94
Role of Notch signaling in neurovascular aging and Alzheimer’s disease
Kapoor, A., & Nation, D. A. (2020) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2020.12.011 · Cited by 95
Associations of White Matter Hyperintensities with Cognitive Decline: A Longitudinal Study
Wang, Y.-L., Chen, W., Cai, W.-J., Hu, H., Xu, W., Wang, Z.-T., Cao, X.-P., Tan, L., Yu, J.-T., & Initiative, A. D. N. (2020) · Journal of Alzheimer’s Disease · doi:10.3233/jad-191005 · Cited by 92
Kellar, D., Lockhart, S. N., Aisen, P. S. S., Raman, R., Rissman, R. A., Brewer, J. B., & Craft, S. (2021) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2021.14 · Cited by 92
Association of White Matter Hyperintensities and Cardiovascular Disease
Moroni, F., Ammirati, E., Hainsworth, A. H., & Camici, P. G. (2020) · Circulation Cardiovascular Imaging · doi:10.1161/circimaging.120.010460 · Cited by 89
Tayler, H. M., Miners, J. S., Güzel, Ö., MacLachlan, R. A., & Love, S. (2021) · Brain Pathology · doi:10.1111/bpa.12935 · Cited by 90
Arfanakis, K., Evia, A. M., Leurgans, S. E., Cardoso, L. F. C., Kulkarni, A. P., Alqam, N., Lopes, L. F., Vieira, D. M., Bennett, D. A., & Schneider, J. A. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-190687 · Cited by 87
Wei, K., Tran, T. T., Chu, K. C. W., Borzage, M., Braskie, M. N., Harrington, M. G., & King, K. S. (2019) · Brain and Behavior · doi:10.1002/brb3.1457 · Cited by 87
Levit, A., Hachinski, V., & Whitehead, S. N. (2020) · GeroScience · doi:10.1007/s11357-020-00164-6 · Cited by 96
The pathobiology of neurovascular aging
Santisteban, M. M., & Iadecola, C. (2025) · Neuron · doi:10.1016/j.neuron.2024.12.014 · Cited by 102
Is tau in the absence of amyloid on the Alzheimer’s continuum?: A study of discordant PET positivity
Weigand, A. J., Bangen, K. J., Thomas, K. R., Delano‐Wood, L., Gilbert, P. E., Brickman, A. M., Bondi, M. W., & Initiative, A. D. N. (2019) · Brain Communications · doi:10.1093/braincomms/fcz046 · Cited by 93
Oligodendrocytes in Alzheimer’s disease pathophysiology
Kedia, S., & Simons, M. (2025) · Nature Neuroscience · doi:10.1038/s41593-025-01873-x · Cited by 86
Puzo, C. J., Labriola, C., Sugarman, M. A., Tripodis, Y., Martin, B. M., Palmisano, J. N., Steinberg, E. G., Stein, T. D., Kowall, N. W., McKee, A. C., et al. (2019) · Alzheimer s Research & Therapy · doi:10.1186/s13195-019-0521-0 · Cited by 85
White matter hyperintensities and CSF Alzheimer disease biomarkers in preclinical Alzheimer disease
Soldan, A., Pettigrew, C. A., Zhu, Y., Wang, M., Moghekar, A., Gottesman, R. F., Singh, B., Martinez, O., Fletcher, E. M., DeCarli, C. S., et al. (2019) · Neurology · doi:10.1212/wnl.0000000000008864 · Cited by 82
Alzheimer’s Disease Neuropathological Comorbidities are Common in the Younger-Old
Beach, T. G., & Malek‐Ahmadi, M. H. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-201213 · Cited by 88
Cerebral Hypoperfusion and the Energy Deficit in A lzheimer's Disease
Love, S., & Miners, J. S. (2016) · Brain Pathology · doi:10.1111/bpa.12401 · Cited by 86
Roseborough, A. D., Saad, L., Goodman, M., Cipriano, L. E., Hachinski, V. C., & Whitehead, S. N. (2023) · Alzheimer's & Dementia · doi:10.1002/alz.12642 · Cited by 80
Brain amyloid and vascular risk are related to distinct white matter hyperintensity patterns
Pålhaugen, L., Sudre, C. H., Tecelao, S., Nakling, A., Almdahl, I. S., Kalheim, L. F., Cardoso, M. J., Johnsen, S. H., Rongve, A., Aarsland, D., et al. (2021) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x20957604 · Cited by 79
Rizvi, B., Lao, P. J., Chesebro, A. G., Dworkin, J. D., Amarante, E., Beato, J. M., Gutierrez, J., Zahodne, L. B., Schupf, N., Manly, J. J., et al. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.25166 · Cited by 79
Self-citationAlosco, M. L., Sugarman, M. A., Besser, L. M., Tripodis, Y., Martin, B. M., Palmisano, J. N., Kowall, N. W., Au, R., Mez, J., DeCarli, C. S., et al. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180017 · Cited by 76
Dadar, M., Manera, A. L., Ducharme, S., & Collins, D. L. (2022) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2021.11.007 · Cited by 78
White matter signal abnormalities in former National Football League players
Alosco, M. L., Koerte, I. K., Tripodis, Y., Mariani, M. L., Chua, A. S., Jarnagin, J., Rahimpour, Y., Puzo, C. J., Healy, R. C., Martin, B. M., et al. (2017) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2017.10.003 · Cited by 76
An MRI measure of degenerative and cerebrovascular pathology in Alzheimer disease
Brickman, A. M., Tosto, G., Gutierrez, J., Andrews, H., Gu, Y., Narkhede, A., Rizvi, B. M., Guzmán, V., Manly, J. J., Vonsattel, J. P., et al. (2018) · Neurology · doi:10.1212/wnl.0000000000006310 · Cited by 73
Weaver, N. A., Doeven, T., Barkhof, F., Biesbroek, J. M., Groeneveld, O. N., Kuijf, H. J., Prins, N. D., Scheltens, P., Teunissen, C. E., van der Flier, W. M., et al. (2019) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2019.08.001 · Cited by 71
Alzheimer‐Related Cerebrovascular Disease in Down Syndrome
Lao, P. J., Gutierrez, J., Keator, D. B., Rizvi, B. M., Banerjee, A., Igwe, K. C., Laing, K. K., Sathishkumar, M. T., Moni, F., Andrews, H., et al. (2020) · Annals of Neurology · doi:10.1002/ana.25905 · Cited by 76
Study, F. T. A., Salvadó, G., Brugulat‐Serrat, A., Sudre, C. H., Grau‐Rivera, O., Suárez‐Calvet, M., Falcón, C., Fauria, K., Cardoso, M. J., Barkhof, F., et al. (2019) · Alzheimer s Research & Therapy · doi:10.1186/s13195-018-0460-1 · Cited by 77
White matter injury across neurodegenerative disease
Festa, L. K., Grinspan, J. B., & Jordan‐Sciutto, K. L. (2023) · Trends in Neurosciences · doi:10.1016/j.tins.2023.11.003 · Cited by 80
Chronic cerebral hypoperfusion: An undefined, relevant entity
Ciacciarelli, A., Sette, G., Giubilei, F., & Orzi, F. (2020) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2020.01.026 · Cited by 70
VEGFR1 and VEGFR2 in Alzheimer’s Disease
Harris, R., Miners, J. S., Allen, S. J., & Love, S. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-170745 · Cited by 70
Myelin in Alzheimer’s disease: culprit or bystander?
Maitre, M., Jeltsch-David, H., Okechukwu, N. G., Klein, C., Patte-Mensah, C., & Mensah-Nyagan, A.-G. (2023) · Acta Neuropathologica Communications · doi:10.1186/s40478-023-01554-5 · Cited by 66
Zahodne, L. B., Mayeda, E. R., Hohman, T. J., Fletcher, E., Racine, A. M., Gavett, B. E., Manly, J. J., Schupf, N., Mayeux, R. P., Brickman, A. M., et al. (2019) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2019.08.009 · Cited by 72
Sugarman, M. A., Zetterberg, H., Blennow, K., Tripodis, Y., McKee, A. C., Stein, T. D., Martin, B. M., Palmisano, J. N., Steinberg, E. G., Simkin, I., et al. (2020) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2020.05.011 · Cited by 68
Regional hyperperfusion in older adults with objectively-defined subtle cognitive decline
Thomas, K. R., Osuna, J., Weigand, A. J., Edmonds, E. C., Clark, A. L., Holmqvist, S. L., Cota, I. H., Wierenga, C. E., Bondi, M. W., Bangen, K. J., et al. (2020) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x20935171 · Cited by 68
Walter, S., Jumpertz, T., Hüttenrauch, M., Ogorek, I., Gerber, H., Storck, S. E., Zampar, S., Dimitrov, M., Lehmann, S., Lepka, K., et al. (2019) · Acta Neuropathologica · doi:10.1007/s00401-018-1929-5 · Cited by 65
Park, G., Hong, J., Duffy, B. A., Lee, J. M., & Kim, H. (2021) · NeuroImage · doi:10.1016/j.neuroimage.2021.118140 · Cited by 64
Ferroptosis of Microglia in Aging Human White Matter Injury
Adeniyi, P. A., Gong, X., MacGregor, E., Degener-O’Brien, K., McClendon, E., Garcia, M., Romero, O., Russell, J., Srivastava, T., Miller, J. A., et al. (2023) · Annals of Neurology · doi:10.1002/ana.26770 · Cited by 62
Iron Pathophysiology in Alzheimer’s Diseases
Wang, T., Xu, S.-F., Fan, Y.-G., Li, L.-B., & Guo, C. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-981-13-9589-5_5 · Cited by 64
Sex is a defining feature of neuroimaging phenotypes in major brain disorders
Salminen, L. E., Tubi, M. A., Bright, J. K., Thomopoulos, S. I., Wieand, A., & Thompson, P. M. (2021) · Human Brain Mapping · doi:10.1002/hbm.25438 · Cited by 61
Wardlaw, J. M., Benveniste, H., & Williams, A. (2021) · Annual Review of Physiology · doi:10.1146/annurev-physiol-060821-014521 · Cited by 67
Secondary prevention of Alzheimer’s dementia: neuroimaging contributions
ten Kate, M., Ingala, S., Schwarz, A. J., Fox, N. C., Chételat, G., van Berckel, B. N. M., Ewers, M., Foley, C., Gispert, J. D., Hill, D., et al. (2018) · Alzheimer s Research & Therapy · doi:10.1186/s13195-018-0438-z · Cited by 65
Lamar, M., Boots, E. A., Arfanakis, K., Barnes, L. L., & Schneider, J. A. (2020) · Neuropsychology Review · doi:10.1007/s11065-020-09460-6 · Cited by 60
Venous Collagenosis as Pathogenesis of White Matter Hyperintensity
Lahna, D. L., Schwartz, D. L., Woltjer, R. L., Black, S. E., Roese, N. E., Dodge, H. H., Boespflug, E. L., Keith, J. L., Gao, F., Ramirez, J., et al. (2022) · Annals of Neurology · doi:10.1002/ana.26487 · Cited by 61
Slow-Wave Sleep and MRI Markers of Brain Aging in a Community-Based Sample
Baril, A., Beiser, A., Mysliwiec, V., Sanchez, E., DeCarli, C. S., Redline, S. S., Gottlieb, D. J., Maillard, P., Romero, J. R., Satizábal, C. L., et al. (2020) · Neurology · doi:10.1212/wnl.0000000000011377 · Cited by 59
Functions and dysfunctions of oligodendrocytes in neurodegenerative diseases
Han, S.-W., Gim, Y., Jang, E., & Hur, E. (2022) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2022.1083159 · Cited by 67
Alzheimer’s dementia: pathogenesis and impact of cardiovascular risk factors on cognitive decline
Wanleenuwat, P., Iwanowski, P. S., & Kozubski, W. P. (2019) · Postgraduate Medicine · doi:10.1080/00325481.2019.1657776 · Cited by 58
Blood Pressure and Vascular Cognitive Impairment
Levine, D. A., Springer, M. V., & Brodtmann, A. G. (2022) · Stroke · doi:10.1161/strokeaha.121.036140 · Cited by 63
Schultz, S. A., Strain, J. F., Adedokun, A., Wang, Q., Preische, O., Kühle, J., Flores, S. E., Keefe, S., Dincer, A., Ances, B. M., et al. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.104960 · Cited by 58
Metadata
- Authors
- Lee, S., Viqar, F., Zimmerman, M. E., Narkhede, A., Tosto, G., Benzinger, T. L. S., Marcus, D. S., Fagan, A. M., Goate, A., Fox, N. C., Cairns, N. J., Holtzman, D. M., Buckles, V., Ghetti, B., McDade, E., Martins, R. N., Saykin, A. J., Masters, C. L., Ringman, J. M., Ryan, N. S., Förster, S., Laske, C., Schofield, P. R., Sperling, R. A., Salloway, S., Correia, S., Jack, C., Weiner, M., Bateman, R. J., Morris, J. C., Mayeux, R., Brickman, A. M., & for the Dominantly Inherited Alzheimer Network
- Affiliations
- New York State Psychiatric Institute (US)
- Fordham University (US)
- Albert Einstein College of Medicine (US)
- Columbia University Irving Medical Center (US)
- NewYork–Presbyterian Hospital (US)
- Washington University in St. Louis (US)
- Icahn School of Medicine at Mount Sinai (US)
- UCL Queen Square Institute of Neurology (GB)
- Indiana University Indianapolis (US)
- Edith Cowan University (AU)
- The University of Melbourne (AU)
- University of Southern California (US)
- German Center for Neurodegenerative Diseases (DE)
- UNSW Sydney (AU)
- Brigham and Women's Hospital (US)
- Brown University (US)
- Mayo Clinic (US)
- San Francisco VA Medical Center (US)
- Corresponding author
- Brickman, Adam M.
- ORCID
- Lee, Seonjoo
- Zimmerman, Molly E.
- Tosto, Giuseppe
- Benzinger, Tammie L.S.
- Marcus, Daniel S.
- Fagan, Anne M.
- Goate, Alison
- Fox, Nick C.
- Holtzman, David M.
- Ghetti, Bernardino
- McDade, Eric
- Martins, Ralph N.
- Saykin, Andrew J.
- Masters, Colin L.
- Ringman, John M.
- Ryan, Natalie S.
- Förster, Stefan
- Laske, Christoph
- Schofield, Peter R.
- Sperling, Reisa A.
- Salloway, Stephen
- Correia, Stephen
- Jack, Clifford
- Weiner, Michael
- Bateman, Randall J.
- Morris, John C.
- Mayeux, Richard
- Brickman, Adam M.
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 2016-04-27
- Volume
- 79
- Issue
- 6
- Pages
- 929-939
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- PMC
- PMC4884146
- OpenAlex
- W2309640507
- Cited by
- 542
- References
- 51
- Citations by year
- 2026: 49 · 2025: 58 · 2024: 53 · 2023: 68 · 2022: 65 · 2021: 65 · 2020: 66 · 2019: 46 · 2018: 38 · 2017: 25 · 2016: 8
- FWCI
- 34.63
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Annals of Neurology (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- UNSWorks (UNSW Sydney) (submittedVersion, cc-by-nc-nd)
- Australasian Journal of Paramedicine (submittedVersion)
- Deep Blue (University of Michigan) (submittedVersion)
- Minerva Access (University of Melbourne) (submittedVersion)
- mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion)
- DZNE Pub (submittedVersion)
- IUScholarWorks (Indiana University) (submittedVersion)
- Purdue University Indianapolis (Indiana University) (submittedVersion)
- PMC
- Funders
- NIH/NIA (U19 AG032438, AG051348)
- NIHR Queen Square Dementia BRU
- German Center for Neurodegenerative Diseases (DZNE)
- Brain Exit Foundation Fellowship
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Clinical Neurology › Cerebrovascular and genetic disorders
- Keywords
- white matter hyperintensities, Alzheimer's disease, autosomal dominant Alzheimer's disease, presymptomatic carriers, presenilin 1, presenilin 2, APP, cerebral small vessel disease, genetic risk
- MeSH terms
- Adult, Alzheimer Disease, Female, Heterozygote, Humans, Magnetic Resonance Imaging, Male, Peptide Fragments, Biomarkers, Case-Control Studies, Amyloid beta-Peptides, Amyloid beta-Protein Precursor, tau Proteins, Genetic Predisposition to Disease, Presenilin-1, Presenilin-2, Young Adult, Neuroimaging, White Matter
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
